This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Cancer; thrombosis	Plasminogen activator inhibitor 1 (SERPINE1; PAI1)	<i>In vitro</i> and mouse studies suggest enhancing the interaction of PAI1 with the N-terminal region of prolactin (PRL) could help inhibit angiogenesis and treat thrombosis or cancer. In human endothelial cells, the N-terminal region of prolactin, 16K PRL, bound the angiogenesis promoter PAI1. In mice implanted with murine melanoma or mammary cancer cells, 16K PRL decreased angiogenesis and tumor growth compared with vehicle. In a mouse model of systemic thrombosis, 16K PRL increased survival compared with vehicle. Next steps could include studies in additional models of thrombosis-related diseases. IMMD Inc. has IMD-4852, a PAI1 inhibitor, in preclinical development to treat thrombosis.	Patent application filed; available for licensing for thrombosis-related diseases	Bajou, K. <i>et al. Nat. Med.</i> ; published online June 15, 2014; doi:10.1038/nm.3552 Contact: Ingrid Struman, University of Liège, Liège, Belgium e-mail: i.struman@ulg.ac.be
<i>SciBX</i> 7(28); doi:10.1038/scibx.2014.838 Published online July 24, 2014				